Patient Advocacy

Amplifying the patient voice to improve the speed and quality of research. The IASLC is proud to support and partner with various patient advocacy groups, patient research advocates, and patient advocates from around the globe.
Pat Adv_landing_donate

The past decade has shown tremendous advances in the care of patients with lung cancer. With improved survival comes the opportunity for patients to become survivors who advocate for research by attending conferences, forming relationships with physicians and care providers, and lending their voices through committee involvement and speaking opportunities. The IASLC offers several opportunities to help transform patients into patient research advocates.

Spotlight

Image
jennifer king
WCLC Advocates Discuss: Neoadjuvant Chemotherapy-alone vs Chemoradiation followed by Sleeve Resection for Locally Advanced Non-Small Cell Lung Cancer
The important take-home from this study is that the addition of radiation therapy did not improve overall survival outcomes and more patients in that chemoradiation group had died 90 days after surgery.
Language Guide page 1

IASLC Language Guide

The following Language Guide has been developed by members of the IASLC to provide guidelines on best practices with common phrases used during presentations at IASLC conferences and within submitted abstracts.

WCLC 2021 Patient Advocate Presentations

Words Matter

Watch Jill Feldman's WCLC 2021 presentation on how stigmatizing words affect patients and their families.

Treatment Patterns in patients with EGFR-positive lung cancer: A real-world patient-report

Treatment Patterns in Patients With EGFR Positive Lung Cancer A Real-World Patient-Report

Watch this WCLC 2021 Presentation by Ivy Elkins on Treatment Patterns in Patients with EGFR Positive Lung Cancer: A Real World Patient Report.

I didn't Smoke Language and Stigma Surrounding Lung Cancer (Personal Experience)

‘I Didn’t Smoke’ Language and Stigma Surrounding Lung Cancer Personal Experience

Gina Hollenbeck, RN BSN shares her personal experience with language and stigma surrounding lung cancer.

Advocates at Work

Patient Advocate Lisa Briggs on Impact of Depression, Anxiety, and Distress in Patients During COVID-19

Read Patient  Advocates discussion...Lisa Briggs on Effects of Depression, Anxiety, and Distress on Changes to Primary Treatment During COVID-19

As patients with lung cancer already present as a vulnerable population group with traditionally poorer survival outcomes, we do not have time to wait. 

Dr. D. Ross Camidge on Teliso-V Monotherapy in Patients With Previously Treated c-Met+ Advanced NSCLC

Dr. D Ross Camidge on Teliso-V Monotherapy in Patients With Previously Treated c-Met+ Advanced NSCLC

Watch as Dr. D. Ross Camidge discusses his presentations on  Teliso-V Monotherapy in Patients With Previously Treated c-Met+ Advanced NSCLC presented at WCLC 2021. 

John Hallick: Scientists and Clinicians are broadening their thinking beyond TKIs

John Hallick: Scientists and clinicians are broadening their thinking beyond TKIs

Patients should also be aware of the typical side effects regarding amivantamab, the majority of which are related to the body’s reaction to the initial infusion. 

Phase I studies of DZD9008, an oral selective EGFR/HER2 inhibitor for patients with advanced NSCLC and EGFR Exon20 insertion mutations

Marcia Horn

I am hopeful that this drug will join the list of targeted agents that are extending the lives of heavily pretreated patients who have experienced disease progression...

Mobocertinib for Patients with EGFR Exon 20 Insertion-Positive Metastatic NSCLC with Disease Progression on Prior EGFR TKI Therapy

Marcia Horn

We look forward to the U.S. Food and Drug Administration’s approval of this Breakthrough Therapy-designated EGFR tyrosine kinase inhibitor (TKI) in the coming months.

Jill Feldman Discusses the IASLC Language Guide

Jill Feldman on the IASLC Language Guide

Jill Feldman highlights the importance of person-first language when writing and presenting on lung cancer data.

Ivy Elkins Discusses Real-World Treatment Patterns for Patients with EGFR-Positive Lung Cancer

Watch as Ivy Elkins, Co-Founder of the EGFR Resisters, comments her WCLC 2021 Presentation, Real-World Treatment Patterns for Patients with EGFR-Positive Lung Cancer

Listen as Ivy Elkins, Co-Founder of the EGFR Resisters, comments her WCLC 2021 Presentation, Real-World Treatment Patterns for Patients with EGFR-Positive Lung Cancer

Ivy Elkins on Pembroluzumab in Combination with Platinum-Based Chemo in Recurrent EGFR/ALK+ NSCLC

Ivy Elkins discusses Shirish M. Gadgeel's WCLC 2021 presentation Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Ivy Elkins discusses Pembrolizumab in Combination With Platinum-Based Chemotherapy in Recurrent EGFR/ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer Disparities Are Indeed A Global Burden…and A Global Challenge

Vivek Tomar

It is the responsibility of each one of us as part of the IASLC community to ensure that such cruel disparities in lung cancer care are overcome...

Jill Feldman on Improving Tobacco Cessation Among Individuals Undergoing Lung Cancer Screening

Jill Feldman on Improving Tobacco Cessation Among Individuals Undergoing Lung Cancer Screening

Jill Feldman discusses April Plank's WCLC 2021 presentation "Improving Tobacco Cessation Among Individuals Undergoing Lung Cancer Screening."

Amy C. Moore, PhD discusses the EPICAL Trial

Amy Moore discusses EPICAL Trial

Amy C. Moore, PhD discusses the EPICAL Trial- a phase IB study combining anti-epidermal growth factor (EGF) vaccination with afatinib in EGFR-mutant NSCLC.

Angus Pratt Discusses Medical Assistance in Dying (MAiD) in Lung Cancer

Angus Pratt on Medical Assistance in Dying in Patients with Lung Cancer

Watch as Angus Pratt Discusses Medical Assistance in Dying (MAiD) in Lung Cancer.

Dr. Upal Basu Roy discusses survival data for patients with stage III NSCLC

Advocates Discuss

Watch as Dr. Upal Basu Roy discusses survival data for patients with Stage III NSCLC.

Advocacy Opportunities for IASLC Members

Pat Adv_landing_CCT Award box

Cancer Care Team Award

Nominate your care team for outstanding provision of care.

Pat Adv_landing_STARS box

STARS

Learn how to read journal articles, understand clinical trial design, and communicate effectively with scientists and physicians regarding novel research. Apply to STARS today.

Patient Advocate Committee

Pat Advoc_committee

Apply for a position on the IASLC Patient Advocate Committee.

Pair Up With an IASLC Patient Advocate Partner

Pat Adv_landing_Pair Up box

Contact us at [email protected] to be paired with an advocacy group based on your patient story.

Become a Member

Pat Adv_landing_Join

Contact us about the complimentary membership for patients and advocates.

We proudly partner with 13+ advocacy organizations to advance the care of patients with lung cancer in patient-driven ways that focus on quality of care and quality of life.
Image
Pat Adv_LCRF logo
Image
Pat Adv_Breath of Hope logo
Image
Research Advocacy Network - Advocate Institute_Logo
Image
Lungevity_Logo
Image
LiveLung_Logo
Image
LungFoundationNZ
Image
Pat Adv_GO2 Foundation logo
Image
Pat_Adv_Merel_Mtn_Foundation_logo
Image
Free_ME_fromLungCancer_Logo
Image
Lung Cancer Awareness Month
Image
Global Lung Cancer Coalition
Image
ALK Positive Logo

Tools for Advocate Involvement

Image
JTO cover 1

Journals

Learn about novel research and clinical care advances.
Image
Liquid Biopsy_Hero Slider

Featured Meeting

Learn about novel research and clinical care advances.
Image
Patient Advocacy_landing_banner

Share Your Story of Your Patient Research Advocate Journey

Learn about novel research and clinical care advances.

Interested in Learning More with the IASLC for Advocacy Efforts/Program?

Interested in Learning More about the IASLC's Advocacy Programs? Contact us at [email protected] to meet our advocacy-focused staff, share your story, and learn more about advocacy opportunities

Give Five!

The International Lung Cancer Foundation is excited about our newest donation functionality: recurring monthly donations! Donors now have the option to make their donations monthly recurring donations with just a few clicks of their mouse.

To help kick off our recurring donations program, we’re asking YOU to give five: $5 (or more!) each month for the next five months (or more!). If 5% of our members (approximately 400 people) gave five, we would raise USD 10,000 to inspire hope through research. Every dollar donated to the ILCF supports our Research Awards program, a global education initiative providing Fellowships and Young Investigator Awards that fund innovative research in lung cancer.